FRANKFURT (Reuters) – Germany’s BioNTech SE said the COVID-19 vaccine it is developing with partner Pfizer will likely generate up to 17 billion euros ($19.6 billion) in revenues this year, as booster shots take hold and use in children increases.
Based on planned deliveries of up to 2.5 billion doses so far, BioNTech said in a statement on Tuesday that it expects 16 billion to 17 billion euros in revenue accruing to it from the vaccine this year, up from a forecast in August of 15.9 billion euros.
That figure includes milestone payments from partners and a share of gross profit in its partners’ territories, the company added.
Pfizer, for its part, last week said it expected to book $36 billion in 2021 sales of the COVID-19 vaccine and forecast another $29 billion from the shot in 2022, topping analyst estimates for both years.
(Reporting by Ludwig Burger and Patricia Weiss)
